Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASND NASDAQ:PTGX NYSE:RDY NASDAQ:SMMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$199.15-3.0%$199.34$118.03▼$216.45$12.36B0.41482,715 shs266,241 shsPTGXProtagonist Therapeutics$75.03-2.2%$63.00$33.31▼$93.25$4.67B2.21.01 million shs501,482 shsRDYDr. Reddy's Laboratories$14.73-0.2%$14.31$12.26▼$16.17$12.29B0.41.65 million shs291,844 shsSMMTSummit Therapeutics$18.86-5.9%$22.32$15.55▼$36.91$14.05B-1.133.81 million shs3.25 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S-2.51%-1.54%+3.81%+23.96%+57.98%PTGXProtagonist Therapeutics-1.01%-3.09%+23.34%+39.52%+63.34%RDYDr. Reddy's Laboratories+2.08%+2.65%-0.84%+2.15%-7.52%SMMTSummit Therapeutics-4.57%-12.65%+6.03%-24.53%-5.56%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$199.15-3.0%$199.34$118.03▼$216.45$12.36B0.41482,715 shs266,241 shsPTGXProtagonist Therapeutics$75.03-2.2%$63.00$33.31▼$93.25$4.67B2.21.01 million shs501,482 shsRDYDr. Reddy's Laboratories$14.73-0.2%$14.31$12.26▼$16.17$12.29B0.41.65 million shs291,844 shsSMMTSummit Therapeutics$18.86-5.9%$22.32$15.55▼$36.91$14.05B-1.133.81 million shs3.25 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S-2.51%-1.54%+3.81%+23.96%+57.98%PTGXProtagonist Therapeutics-1.01%-3.09%+23.34%+39.52%+63.34%RDYDr. Reddy's Laboratories+2.08%+2.65%-0.84%+2.15%-7.52%SMMTSummit Therapeutics-4.57%-12.65%+6.03%-24.53%-5.56%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASNDAscendis Pharma A/S 2.94Moderate Buy$249.8024.91% UpsidePTGXProtagonist Therapeutics 2.83Moderate Buy$74.00-2.28% DownsideRDYDr. Reddy's Laboratories 2.83Moderate Buy$16.9514.80% UpsideSMMTSummit Therapeutics 2.50Moderate Buy$31.1460.78% UpsideCurrent Analyst Ratings BreakdownLatest PTGX, SMMT, ASND, and RDY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/21/2025SMMTSummit TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$50.00 ➝ $40.0010/21/2025SMMTSummit TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetUnderweight$13.00 ➝ $16.0010/20/2025SMMTSummit TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$35.00 ➝ $40.0010/20/2025SMMTSummit TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$40.0010/17/2025PTGXProtagonist TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$72.00 ➝ $96.0010/17/2025ASNDAscendis Pharma A/SRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy$271.0010/16/2025ASNDAscendis Pharma A/SRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy10/13/2025ASNDAscendis Pharma A/SCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$203.00 ➝ $254.0010/13/2025PTGXProtagonist TherapeuticsBMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform10/13/2025PTGXProtagonist TherapeuticsJohnson RiceSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$112.0010/13/2025SMMTSummit TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold(Data available from 10/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASNDAscendis Pharma A/S$393.54M31.35N/AN/A($1.88) per share-106.37PTGXProtagonist Therapeutics$434.43M10.84$4.41 per share17.16$11.33 per share6.68RDYDr. Reddy's Laboratories$334.26B0.04$1.06 per share13.99$4.73 per share3.12SMMTSummit TherapeuticsN/AN/AN/AN/A$0.53 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASNDAscendis Pharma A/S-$409.12M-$5.16N/A833.24N/A-54.94%N/A-24.31%11/13/2025 (Estimated)PTGXProtagonist Therapeutics$275.19M$0.70108.18N/AN/A24.88%8.12%7.41%11/6/2025 (Estimated)RDYDr. Reddy's Laboratories$663M$0.6622.3718.015.6916.99%17.25%11.63%11/4/2025 (Estimated)SMMTSummit Therapeutics-$221.32M-$1.01N/AN/AN/AN/A-208.64%-181.28%N/ALatest PTGX, SMMT, ASND, and RDY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/13/2025Q3 2025ASNDAscendis Pharma A/S-$0.49N/AN/AN/AN/AN/A11/6/2025Q3 2025PTGXProtagonist Therapeutics-$0.59N/AN/AN/A$5.41 millionN/A11/4/2025Q2 25/26RDYDr. Reddy's Laboratories$0.18N/AN/AN/AN/AN/A10/20/2025Q3 2025SMMTSummit Therapeutics-$0.14-$0.31-$0.17-$0.31$77.16 millionN/A8/11/2025Q2 2025SMMTSummit Therapeutics-$0.10-$0.76-$0.66-$0.76N/AN/A8/7/2025Q2 2025ASNDAscendis Pharma A/S-$1.42-$0.93+$0.49-$0.93$163.17 million$216.28 million8/6/2025Q2 2025PTGXProtagonist Therapeutics-$0.53-$0.55-$0.02-$0.55$8.32 million$5.55 million7/23/2025Q1 25/26RDYDr. Reddy's Laboratories$0.18$0.20+$0.02$0.20$88.27 billion$988.82 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASNDAscendis Pharma A/SN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/ARDYDr. Reddy's Laboratories$0.070.48%N/A10.61%N/ASMMTSummit TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASNDAscendis Pharma A/SN/A1.020.69PTGXProtagonist TherapeuticsN/A16.9716.97RDYDr. Reddy's Laboratories0.011.891.36SMMTSummit TherapeuticsN/A5.135.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASNDAscendis Pharma A/SN/APTGXProtagonist Therapeutics98.63%RDYDr. Reddy's Laboratories3.85%SMMTSummit Therapeutics4.61%Insider OwnershipCompanyInsider OwnershipASNDAscendis Pharma A/S40.00%PTGXProtagonist Therapeutics4.90%RDYDr. Reddy's Laboratories2.00%SMMTSummit Therapeutics84.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASNDAscendis Pharma A/S1,01761.69 million37.02 millionOptionablePTGXProtagonist Therapeutics12062.21 million59.16 millionOptionableRDYDr. Reddy's Laboratories27,811834.93 million818.23 millionOptionableSMMTSummit Therapeutics110742.85 million112.17 millionOptionablePTGX, SMMT, ASND, and RDY HeadlinesRecent News About These CompaniesSMMT's Q3 Loss Wider Than Expected, Stock Down on Study Amendments1 hour ago | zacks.comSummit Therapeutics price target lowered to $32 from $33 at Clear Street4 hours ago | msn.comSummit Therapeutics (NASDAQ:SMMT) Announces Quarterly Earnings ResultsOctober 21 at 7:22 AM | marketbeat.comSummit Therapeutics Inc. (SMMT) Q3 2025 Earnings Call TranscriptOctober 20 at 6:01 PM | seekingalpha.comSummit Therapeutics (NASDAQ:SMMT) Shares Gap Down - Here's WhyOctober 20 at 3:45 PM | marketbeat.comSummit's Bold BLA Without Stat-Sig OS: Why I Step Back To HoldOctober 20 at 3:12 PM | seekingalpha.comSummit Therapeutics Inc. 2025 Q3 - Results - Earnings Call PresentationOctober 20 at 2:30 PM | seekingalpha.comSummit Therapeutics Sees Unusually High Options Volume (NASDAQ:SMMT)October 20 at 11:47 AM | marketbeat.comSummit Therapeutics' (SMMT) "Market Outperform" Rating Reaffirmed at JMP SecuritiesOctober 20 at 9:56 AM | marketbeat.comSummit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025October 20 at 7:01 AM | businesswire.comSummit announces ivonescimab, chemo showed improvement in primary endpointOctober 19 at 5:27 PM | msn.comIvonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in ChinaOctober 19 at 10:30 AM | businesswire.comSummit Therapeutics PLC $SMMT Holdings Trimmed by TD Asset Management IncOctober 19 at 4:13 AM | marketbeat.comSummit Therapeutics (SMMT) Projected to Post Quarterly Earnings on MondayOctober 19 at 2:52 AM | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTOctober 18 at 10:00 AM | prnewswire.comAn Overview of Summit Therapeutics's EarningsOctober 17, 2025 | benzinga.comSummit Therapeutics (SMMT) Expected to Announce Earnings on MondayOctober 17, 2025 | marketbeat.comSummit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal CancerOctober 17, 2025 | businesswire.comSummit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025October 15, 2025 | finance.yahoo.comSummit Therapeutics (NASDAQ:SMMT) Upgraded at Zacks ResearchOctober 15, 2025 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Stock Price Down 4.9% - Time to Sell?October 14, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePTGX, SMMT, ASND, and RDY Company DescriptionsAscendis Pharma A/S NASDAQ:ASND$199.15 -6.06 (-2.95%) As of 03:32 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.Protagonist Therapeutics NASDAQ:PTGX$75.03 -1.69 (-2.20%) As of 03:32 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.Dr. Reddy's Laboratories NYSE:RDY$14.72 -0.03 (-0.17%) As of 03:32 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.Summit Therapeutics NASDAQ:SMMT$18.86 -1.18 (-5.87%) As of 03:32 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas WesBanco Insiders Signal Confidence With Coordinated Buys Will D-Wave's European Expansion Keep Fueling the Rally? Navitas Soars 78% on NVIDIA Update: Is This Rally Sustainable? Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Waymo’s Global Expansion Strengthens the Case for GOOGL Stock Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Meta vs OpenAI: Is Sora a True Threat to Meta's Dominance? Institutions Are Fueling CrowdStrike’s Next Leg Higher Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
